SpectraCure AB (publ) (SPEC.ST)
SEK 3.59
(15.81%)
SEK 3.59
(15.81%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 318 Thousand SEK | -41.0% |
| 2022 | 539 Thousand SEK | 0.0% |
| 2021 | - SEK | -100.0% |
| 2020 | 1211.00 SEK | 58.72% |
| 2019 | 763.00 SEK | -99.87% |
| 2018 | 596 Thousand SEK | 130.16% |
| 2017 | 258.95 Thousand SEK | 49.76% |
| 2016 | 172.91 Thousand SEK | -77.79% |
| 2015 | 778.5 Thousand SEK | 63.48% |
| 2014 | 476.19 Thousand SEK | -68.04% |
| 2013 | 1.49 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - SEK | -100.0% |
| 2024 Q1 | 5.43 Million SEK | 1609.43% |
| 2023 FY | 318 Thousand SEK | -41.0% |
| 2023 Q1 | 6.97 Million SEK | 1194.81% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q2 | - SEK | -100.0% |
| 2023 Q4 | 318 Thousand SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q4 | 539 Thousand SEK | 0.0% |
| 2022 FY | 539 Thousand SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 FY | - SEK | -100.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q4 | 1.21 Million SEK | 0.0% |
| 2020 FY | 1211.00 SEK | 58.72% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 FY | 763.00 SEK | -99.87% |
| 2019 Q4 | 763 Thousand SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q4 | 596 Thousand SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | 596 Thousand SEK | 130.16% |
| 2017 Q1 | 16 Thousand SEK | -30.43% |
| 2017 FY | 258.95 Thousand SEK | 49.76% |
| 2017 Q2 | 112.79 Thousand SEK | 604.99% |
| 2017 Q3 | 77.8 Thousand SEK | -31.02% |
| 2017 Q4 | 52.35 Thousand SEK | -32.71% |
| 2016 Q3 | 29.77 Thousand SEK | 33.12% |
| 2016 Q1 | 97.78 Thousand SEK | -34.97% |
| 2016 Q4 | 22.99 Thousand SEK | -22.75% |
| 2016 FY | 172.91 Thousand SEK | -77.79% |
| 2016 Q2 | 22.36 Thousand SEK | -77.13% |
| 2015 Q1 | 403.08 Thousand SEK | 69.33% |
| 2015 Q4 | 150.37 Thousand SEK | 19.61% |
| 2015 Q3 | 125.72 Thousand SEK | -29.77% |
| 2015 Q2 | 179.02 Thousand SEK | -55.59% |
| 2015 FY | 778.5 Thousand SEK | 63.48% |
| 2014 FY | 476.19 Thousand SEK | -68.04% |
| 2014 Q1 | 293.27 Thousand SEK | 0.0% |
| 2014 Q2 | 191.56 Thousand SEK | -34.68% |
| 2014 Q3 | 395.18 Thousand SEK | 106.3% |
| 2014 Q4 | 238.04 Thousand SEK | -39.76% |
| 2013 FY | 1.49 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | 94.905% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.977% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.977% |
| Arcoma AB | 163.01 Million SEK | 99.805% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 99.844% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.986% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 99.944% |
| CellaVision AB (publ) | 677.29 Million SEK | 99.953% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 96.156% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | 67.427% |
| C-Rad AB (publ) | 424.61 Million SEK | 99.925% |
| Duearity AB (publ) | 1.65 Million SEK | 80.774% |
| Dignitana AB (publ) | 86.06 Million SEK | 99.631% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 96.913% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.999% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | 95.507% |
| Integrum AB (publ) | 104.11 Million SEK | 99.695% |
| Luxbright AB (publ) | 854.69 Thousand SEK | 62.794% |
| Mentice AB (publ) | 273.61 Million SEK | 99.884% |
| OssDsign AB (publ) | 112.15 Million SEK | 99.716% |
| Paxman AB (publ) | 210.11 Million SEK | 99.849% |
| Promimic AB (publ) | 37.07 Million SEK | 99.142% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -30.328% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 98.632% |
| ScandiDos AB (publ) | 60.42 Million SEK | 99.474% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.989% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 99.793% |
| Senzime AB (publ) | 35.75 Million SEK | 99.111% |
| Stille AB | 294.89 Million SEK | 99.892% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.991% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 99.947% |